F2G Ltd. and Shionogi & Co., Ltd. have reported detailed positive Phase 3 results for olorofim, an investigational oral antifungal treatment for invasive aspergillosis, demonstrating non-inferiority to a liposomal amphotericin B-based treatment regimen in patients with limited therapeutic alternatives. The global OASIS trial recorded Day 42 all-cause mortality rates of 23.8% with olorofim and 24.3% with the comparator, while drug-related kidney adverse events occurred substantially less frequently among patients receiving the experimental medicine. The findings strengthen the clinical case for a new class of antifungal treatment, with F2G preparing to resubmit a New Drug Application to the U.S. Food and Drug Administration by the end of 2026.
The results are particularly relevant for immunocompromised patients who cannot receive conventional azole antifungals because of resistance, intolerance, drug interactions or previous treatment failure. Although olorofim demonstrated encouraging efficacy and safety findings, its Phase 3 success does not establish superiority over existing treatment, and important questions remain concerning liver-related adverse effects and longer-term clinical outcomes.
How did oral olorofim perform against amphotericin B in the Phase 3 OASIS trial?
The Phase 3 OASIS study enrolled 225 adults with proven invasive aspergillosis or probable pulmonary invasive aspergillosis who were unable to receive effective mould-active azole treatment. Participants were randomized in a 2:1 ratio, with 151 patients receiving oral olorofim and 74 assigned to intravenous liposomal amphotericin B, marketed as AmBisome, followed by standard-of-care antifungal treatment.
The study’s primary endpoint evaluated all-cause mortality at Day 42 using a prespecified non-inferiority margin of 20 percentage points. Non-inferiority trials are designed to determine whether a new treatment is not unacceptably less effective than an established comparator, rather than demonstrating that it produces superior clinical outcomes.
At Day 42, 36 of 151 olorofim recipients had died, representing 23.8% of the treatment group. The comparator group recorded 18 deaths among 74 participants, equivalent to 24.3%. The difference was -0.5 percentage points, with a 95% confidence interval ranging from -13.1 to 10.8 percentage points, satisfying the trial’s predefined non-inferiority criterion.
These results suggest that olorofim achieved a comparable primary mortality outcome within the study’s statistical framework. However, the confidence interval and relatively wide non-inferiority margin should be considered when interpreting the strength of the evidence, particularly given the seriousness of the underlying infection.
The trial also assessed all-cause mortality at Day 84, providing additional information about outcomes beyond the primary assessment period. Mortality reached 32.5% among patients receiving olorofim compared with 29.7% receiving the comparator regimen, a numerical difference of 2.7 percentage points.
The Day 84 confidence interval ranged from -10.6 to 15.0 percentage points, demonstrating considerable uncertainty around the longer-term comparison. These findings do not establish a survival advantage for either treatment, although they provide important context for the sustained risks facing patients with invasive aspergillosis.
What did the OASIS trial reveal about clinical response and hospital treatment duration?
In addition to mortality, investigators evaluated global clinical response using criteria developed by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer. Successful responses required improvement across clinical, radiological and mycological assessments, providing a more comprehensive measure of infection control than symptom improvement alone.
At Day 42, global response was achieved by 26.5% of patients receiving olorofim compared with 31.1% receiving the comparator regimen. By Day 84, the corresponding response rates were 30.5% and 28.4%, indicating broadly comparable results across the extended observation period.
These findings are clinically relevant because invasive aspergillosis often affects patients with severe underlying medical conditions, making successful infection treatment difficult to assess. Changes in lung imaging, microbiological evidence and clinical condition may not always occur at the same time, particularly in patients recovering from cancer treatment or transplantation.
The study also identified differences in hospitalization duration. Patients receiving olorofim were discharged after an average of 17 days, compared with 28 days among those receiving the amphotericin B-based regimen, with substantial variability in both groups.
A shorter hospitalization period could potentially reduce treatment burden and support outpatient management, particularly because olorofim can be administered orally. However, the reported comparison does not establish that olorofim directly caused earlier discharge, and further analyses would be needed to assess the influence of baseline disease severity, other medical complications and healthcare practices.
The overall findings suggest that oral olorofim may offer a practical alternative for selected patients requiring prolonged antifungal treatment. Nevertheless, any clinical or economic advantage associated with shorter hospitalization must be evaluated independently of the trial’s primary efficacy result.
Why is a new oral antifungal treatment important for resistant invasive aspergillosis?
Invasive aspergillosis is a potentially fatal fungal infection caused by Aspergillus species, commonly affecting patients whose immune defenses have been weakened by hematological malignancies, transplantation or intensive immunosuppressive treatment.
The infection frequently involves the lungs but can spread to other organs, making prompt diagnosis and effective antifungal therapy essential. Treatment becomes especially challenging when conventional azole medications cannot be used because of resistance, clinically significant drug interactions or intolerance.
Approximately 79% of OASIS participants had hematological malignancies and/or had undergone stem cell transplantation, while around 11% had received solid-organ transplants. Approximately 40% were neutropenic at enrollment or shortly before entering the study, reflecting the substantial immunological vulnerability of the enrolled population.
Currently available non-azole options include amphotericin B formulations, which can be effective but require intravenous administration and may cause kidney-related complications. These limitations create a need for additional antifungal agents with distinct mechanisms and manageable toxicity profiles.
Olorofim belongs to the orotomide class of antifungal medicines and targets fungal dihydroorotate dehydrogenase, an enzyme involved in pyrimidine biosynthesis. By interfering with this pathway, the treatment disrupts essential fungal cellular processes through a mechanism distinct from those of existing azole and polyene antifungals.
The drug has demonstrated activity against several Aspergillus species, including strains resistant to azole medicines. This characteristic could be especially valuable when patients experience breakthrough infection during antifungal prophylaxis or cannot tolerate conventional therapies.
John H. Rex, chief medical officer of F2G, indicated that the Phase 3 findings supported the potential of olorofim as a first-in-class treatment for difficult invasive fungal infections. However, the drug’s distinct mechanism does not establish effectiveness against every fungal pathogen, and its clinical use would depend on the organisms and indications ultimately supported by regulatory approval.
Did olorofim demonstrate fewer kidney-related adverse events than the comparator treatment?
The safety findings were among the most clinically significant aspects of the detailed OASIS results. Investigators reported drug-related adverse events in 35.8% of olorofim recipients compared with 63.9% of patients receiving the amphotericin B-based regimen.
The difference was largely associated with kidney-related adverse events, which affected 1.3% of olorofim-treated patients compared with 22.2% of comparator recipients. Serious drug-related adverse events were also reported less frequently with olorofim, occurring in 4.0% compared with 18.1% of patients.
These differences are particularly relevant because kidney complications can restrict antifungal treatment options in patients who are already medically vulnerable. Reduced renal toxicity could potentially allow physicians greater flexibility when managing infections in individuals receiving other medications that affect kidney function.
However, the favorable kidney-safety findings must be considered alongside liver-related risks. Expert-adjudicated drug-induced liver injury events considered at least possibly related to treatment occurred in 4.6% of olorofim recipients compared with 4.2% receiving the comparator regimen.
The similar incidence of these liver injury events demonstrates that olorofim is not free of important safety concerns. Liver function monitoring and careful evaluation of drug interactions may remain necessary, depending on the eventual prescribing information and regulatory conclusions.
The findings also need to be interpreted within the trial’s treatment structure, which compared an oral medicine with an intravenous regimen that could subsequently transition to other standard antifungal therapies. Differences in administration, treatment exposure and individual patient characteristics may influence observed adverse-event patterns.
Although the results suggest a potentially favorable renal safety profile, larger post-approval datasets would be needed to identify uncommon adverse effects and characterize outcomes in broader clinical populations.
What comes next for olorofim as F2G and Shionogi prepare regulatory submissions?
F2G intends to resubmit a New Drug Application for olorofim to the U.S. Food and Drug Administration by the end of 2026, using the OASIS findings to support its application. Shionogi will lead regulatory activities in Europe and Asia under the companies’ development and commercialization partnership.
Olorofim has already received several regulatory designations, including U.S. orphan drug status for multiple invasive fungal infections, Qualified Infectious Disease Product designation and Breakthrough Therapy designations for selected serious fungal infections.
These designations reflect the unmet medical needs associated with difficult-to-treat fungal diseases and may provide development or review advantages. However, none constitutes marketing authorization or guarantees that the FDA will determine the treatment’s safety and efficacy to be sufficient for approval.
The companies are also expected to provide further scientific discussion of the OASIS findings at IDWeek 2026, where the data are scheduled for a late-breaking oral presentation. Such presentations may help clinicians assess the trial’s strengths, limitations and potential relevance to existing treatment guidelines.
The development partnership assigns F2G commercial responsibility for North America and territories outside Shionogi’s licensed regions, while Shionogi holds commercial responsibility across Europe and Asia. This structure could support geographically coordinated regulatory submissions and future access strategies if olorofim is approved.
For patients with invasive aspergillosis who cannot benefit from standard azole therapy, the availability of an effective oral antifungal with a novel mechanism could represent an important treatment advance. The OASIS trial provides pivotal evidence supporting that possibility, particularly through its primary mortality endpoint and lower incidence of drug-related renal complications.
Nevertheless, mortality remained substantial in both groups, and the results underscore the continuing severity of invasive aspergillosis among immunocompromised patients. Regulatory assessment will determine whether olorofim’s overall efficacy and safety profile supports its introduction as a new treatment option.
